NASDAQ:ROSG - Rosetta Genomics Stock Price, Price Target & More

$0.3502 -0.02 (-5.40 %)
(As of 04/20/2018 03:06 AM ET)
Previous Close$0.3502
Today's Range$0.35 - $0.38
52-Week Range$0.23 - $2.82
Volume21,940 shs
Average Volume129,943 shs
Market Capitalization$2.19 million
P/E Ratio-0.04
Dividend YieldN/A
Beta0.47

About Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics logoRosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Receive ROSG News and Ratings via Email

Sign-up to receive the latest news and ratings for ROSG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ROSG
CUSIPN/A
Phone972-73-222-0700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-0.04
Forward P/E RatioInfinity
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.23 million
Price / Sales0.22
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book0.15

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees86
Outstanding Shares5,930,000

How to Become a New Pot Stock Millionaire

Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions

What is Rosetta Genomics' stock symbol?

Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."

How were Rosetta Genomics' earnings last quarter?

Rosetta Genomics (NASDAQ:ROSG) released its quarterly earnings data on Thursday, May, 19th. The medical research company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. The medical research company earned $2.60 million during the quarter, compared to the consensus estimate of $3.36 million. View Rosetta Genomics' Earnings History.

When is Rosetta Genomics' next earnings date?

Rosetta Genomics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 23rd 2018. View Earnings Estimates for Rosetta Genomics.

Who are some of Rosetta Genomics' key competitors?

Who are Rosetta Genomics' key executives?

Rosetta Genomics' management team includes the folowing people:
  • Mr. Kenneth A. Berlin, Pres & CEO (Age 54)
  • Mr. Ron Kalfus CPA, Chief Financial Officer (Age 44)
  • Mr. Oded Biran Adv., Gen. Counsel and Sec. (Age 39)
  • Dr. Eti Meiri Ph.D., VP of Research (Age 50)
  • Ms. Ana C. Ward Esq., M.S.,M.B.A., Exec. VP of Legal and Corp. Devel.

Has Rosetta Genomics been receiving favorable news coverage?

News coverage about ROSG stock has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Rosetta Genomics earned a daily sentiment score of 0.21 on Accern's scale. They also assigned news articles about the medical research company an impact score of 45.52 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Rosetta Genomics' major shareholders?

Rosetta Genomics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.93%). View Institutional Ownership Trends for Rosetta Genomics.

How do I buy shares of Rosetta Genomics?

Shares of ROSG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rosetta Genomics' stock price today?

One share of ROSG stock can currently be purchased for approximately $0.3502.

How big of a company is Rosetta Genomics?

Rosetta Genomics has a market capitalization of $2.19 million and generates $9.23 million in revenue each year. The medical research company earns $-16,230,000.00 in net income (profit) each year or ($9.31) on an earnings per share basis. Rosetta Genomics employs 86 workers across the globe.

How can I contact Rosetta Genomics?

Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected]


MarketBeat Community Rating for Rosetta Genomics (ROSG)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  119 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  209
MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe ROSG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ROSG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rosetta Genomics (NASDAQ:ROSG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Rosetta Genomics in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.002.002.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/A$3.50
Price Target Upside: N/AN/AN/A621.65% upside

Rosetta Genomics (NASDAQ:ROSG) Consensus Price Target History

Price Target History for Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics (NASDAQ:ROSG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017Barrington ResearchDowngradeOutperform -> Market PerformHighView Rating Details
1/6/2017AegisReiterated RatingBuy$3.50N/AView Rating Details
9/7/2016S&P Equity ResearchLower Price Target$0.94 -> $0.82N/AView Rating Details
6/13/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Rosetta Genomics (NASDAQ:ROSG) Earnings History and Estimates Chart

Earnings by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics (NASDAQ:ROSG) Earnings Estimates

Next Year EPS Consensus Estimate: $-3.96 EPS

Rosetta Genomics (NASDAQ ROSG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/23/2018N/AView Earnings Details
12/20/2016Q3 2016($1.92)($2.28)$2.63 million$2.20 millionViewN/AView Earnings Details
9/26/2016Q216($0.17)($0.16)$2.89 million$2.41 millionViewListenView Earnings Details
5/19/2016Q116($0.16)($0.18)$3.36 million$2.60 millionViewListenView Earnings Details
3/23/2016Q415($0.33)($0.14)$3.50 million$3.60 millionViewListenView Earnings Details
12/1/2015Q315$0.27$2.43 millionViewN/AView Earnings Details
7/6/2011Q2 2011$395.96ViewN/AView Earnings Details
6/1/2011Q1 2011($66.95)ViewN/AView Earnings Details
4/4/2011Q4 2010($136.07)ViewN/AView Earnings Details
11/30/2010Q3 2010($165.58)($138.23)ViewN/AView Earnings Details
9/7/2010Q2 2010($136.79)($177.82)ViewN/AView Earnings Details
5/26/2010Q1 2010($143.99)($159.10)ViewN/AView Earnings Details
3/31/2010Q4 2009($165.58)($200.86)ViewN/AView Earnings Details
12/18/2009Q3 2009($179.98)($174.22)ViewN/AView Earnings Details
9/8/2009Q2 2009($107.99)($200.86)ViewN/AView Earnings Details
5/21/2009Q1 2009($165.58)$213.82ViewN/AView Earnings Details
3/26/2009Q4 2008($201.58)($181.42)ViewN/AView Earnings Details
12/5/2008Q3 2008($194.38)($177.10)ViewN/AView Earnings Details
8/19/2008Q2 2008($244.78)($223.18)ViewN/AView Earnings Details
5/21/2008Q1 2008($230.38)($233.98)ViewN/AView Earnings Details
2/29/2008Q4 2007($129.59)($175.66)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Rosetta Genomics (NASDAQ:ROSG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Rosetta Genomics (NASDAQ ROSG) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 8.51%
Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
Institutional Ownership by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Rosetta Genomics (NASDAQ ROSG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Healthcare Master Fund SabbyMajor ShareholderBuy119,761$0.42$50,299.62View SEC Filing  
3/13/2018Healthcare Master Fund SabbyMajor ShareholderBuy175,828$0.42$73,847.76View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rosetta Genomics (NASDAQ ROSG) News Headlines

Source:
DateHeadline
Shareholder Meeting Adjourned to April 26, 2018Shareholder Meeting Adjourned to April 26, 2018
finance.yahoo.com - April 17 at 3:34 PM
Rosetta Genomics Ltd.: Rosetta Announces Resignation of CEORosetta Genomics Ltd.: Rosetta Announces Resignation of CEO
www.finanznachrichten.de - April 11 at 9:54 AM
Rosetta Announces Resignation of CEORosetta Announces Resignation of CEO
finance.yahoo.com - April 11 at 9:54 AM
Action Required Before Potential BankruptcyAction Required Before Potential Bankruptcy
finance.yahoo.com - April 10 at 11:04 AM
Contrasting Rosetta Genomics (ROSG) and Prothena (PRTA)Contrasting Rosetta Genomics (ROSG) and Prothena (PRTA)
www.americanbankingnews.com - March 30 at 7:30 PM
Rosetta Genomics (ROSG) Set to Announce Earnings on WednesdayRosetta Genomics (ROSG) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:18 AM
Insider Buying: Rosetta Genomics Ltd. (ROSG) Major Shareholder Purchases 119,761 Shares of StockInsider Buying: Rosetta Genomics Ltd. (ROSG) Major Shareholder Purchases 119,761 Shares of Stock
www.americanbankingnews.com - March 16 at 2:00 PM
Healthcare Master Fund Sabby Acquires 175,828 Shares of Rosetta Genomics Ltd. (ROSG) StockHealthcare Master Fund Sabby Acquires 175,828 Shares of Rosetta Genomics Ltd. (ROSG) Stock
www.americanbankingnews.com - March 14 at 4:48 PM
Rosetta Genomics Ltd.: Genoptix Enters into Agreement to Market and Distribute Rosetta Genomics Testing Services WorldwideRosetta Genomics Ltd.: Genoptix Enters into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide
www.finanznachrichten.de - March 14 at 3:30 PM
Genoptix Enters into Agreement to Market and Distribute Rosetta Genomics Testing Services WorldwideGenoptix Enters into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide
finance.yahoo.com - March 13 at 3:36 PM
Rosetta Genomics Ltd.: Rosetta Sets a New Date for Shareholder Meeting to Approve Genoptix MergerRosetta Genomics Ltd.: Rosetta Sets a New Date for Shareholder Meeting to Approve Genoptix Merger
www.finanznachrichten.de - March 12 at 3:27 PM
Rosetta Sets a New Date for Shareholder Meeting to Approve Genoptix MergerRosetta Sets a New Date for Shareholder Meeting to Approve Genoptix Merger
finance.yahoo.com - March 12 at 3:27 PM
Genoptix Completes Acquisition of PersonalizeDx from Rosetta GenomicsGenoptix Completes Acquisition of PersonalizeDx from Rosetta Genomics
finance.yahoo.com - March 5 at 8:40 AM
Genoptix Enters into New Agreements to Acquire Rosetta Genomics for $9 Million in CashGenoptix Enters into New Agreements to Acquire Rosetta Genomics for $9 Million in Cash
finance.yahoo.com - February 28 at 8:13 AM
Rosetta Genomics Announces Results from Extraordinary General Meeting of Shareholders to Vote on Proposed Merger with GenoptixRosetta Genomics Announces Results from Extraordinary General Meeting of Shareholders to Vote on Proposed Merger with Genoptix
finance.yahoo.com - February 23 at 8:43 AM
Rosetta Genomics Ltd.: Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with GenoptixRosetta Genomics Ltd.: Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix
www.finanznachrichten.de - February 16 at 9:19 AM
Rosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with GenoptixRosetta Genomics Urges Shareholders to Vote FOR the Proposed Merger with Genoptix
finance.yahoo.com - February 16 at 9:19 AM
Head to Head Survey: Portola Pharmaceuticals (PTLA) & Rosetta Genomics (ROSG)Head to Head Survey: Portola Pharmaceuticals (PTLA) & Rosetta Genomics (ROSG)
www.americanbankingnews.com - February 16 at 7:58 AM
Analyzing Rosetta Genomics (ROSG) & Charles River Laboratories Intl. (CRL)Analyzing Rosetta Genomics (ROSG) & Charles River Laboratories Intl. (CRL)
www.americanbankingnews.com - February 10 at 11:08 PM
ValuEngine Upgrades Rosetta Genomics (ROSG) to SellValuEngine Upgrades Rosetta Genomics (ROSG) to Sell
www.americanbankingnews.com - February 4 at 3:24 PM
Reviewing Rosetta Genomics (ROSG) & Iqvia (IQV)Reviewing Rosetta Genomics (ROSG) & Iqvia (IQV)
www.americanbankingnews.com - January 30 at 11:12 PM
Critical Survey: Senomyx (SNMX) and Rosetta Genomics (ROSG)Critical Survey: Senomyx (SNMX) and Rosetta Genomics (ROSG)
www.americanbankingnews.com - January 8 at 12:06 PM
OpGen (OPGN) and Rosetta Genomics (ROSG) Critical SurveyOpGen (OPGN) and Rosetta Genomics (ROSG) Critical Survey
www.americanbankingnews.com - December 28 at 1:13 PM
 Rosetta Genomics Ltd. (ROSG) Receives Consensus Recommendation of "Buy" from Brokerages Rosetta Genomics Ltd. (ROSG) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 26 at 4:07 PM
Dec. 22 Forum Update: "Merry Christmas" EditionDec. 22 Forum Update: "Merry Christmas" Edition
finance.yahoo.com - December 22 at 8:52 PM
Barrington Research Downgrades Rosetta Genomics (ROSG) to Market PerformBarrington Research Downgrades Rosetta Genomics (ROSG) to Market Perform
www.americanbankingnews.com - December 18 at 11:46 AM
Rosetta Genomics (ROSG) Agrees to Sell Business to Genoptix for $10MRosetta Genomics (ROSG) Agrees to Sell Business to Genoptix for $10M
www.streetinsider.com - December 16 at 9:10 AM
Genoptix to Acquire Rosetta Genomics for $10 Million in CashGenoptix to Acquire Rosetta Genomics for $10 Million in Cash
finance.yahoo.com - December 15 at 9:06 AM
Rosetta Genomics (ROSG) and Its Peers Head-To-Head ReviewRosetta Genomics (ROSG) and Its Peers Head-To-Head Review
www.americanbankingnews.com - December 9 at 3:14 AM
Financial Contrast: Rosetta Genomics (ROSG) and Its PeersFinancial Contrast: Rosetta Genomics (ROSG) and Its Peers
www.americanbankingnews.com - December 8 at 9:08 PM
Analyzing Rosetta Genomics (ROSG) and The CompetitionAnalyzing Rosetta Genomics (ROSG) and The Competition
www.americanbankingnews.com - December 8 at 3:30 PM
Rosetta Genomics (ROSG) and Its Peers Head to Head ComparisonRosetta Genomics (ROSG) and Its Peers Head to Head Comparison
www.americanbankingnews.com - December 6 at 1:28 AM
Rosetta Genomics (ROSG) and Its Rivals Financial ComparisonRosetta Genomics (ROSG) and Its Rivals Financial Comparison
www.americanbankingnews.com - December 4 at 7:42 PM
Head to Head Review: Rosetta Genomics (ROSG) versus The CompetitionHead to Head Review: Rosetta Genomics (ROSG) versus The Competition
www.americanbankingnews.com - December 2 at 11:30 PM
Rosetta Genomics (ROSG) Receives NASDAQ Notification on Minimum Bid PriceRosetta Genomics (ROSG) Receives NASDAQ Notification on Minimum Bid Price
www.streetinsider.com - December 2 at 11:09 AM
Analyzing Rosetta Genomics (ROSG) and Its RivalsAnalyzing Rosetta Genomics (ROSG) and Its Rivals
www.americanbankingnews.com - November 22 at 3:42 PM
Rosetta Genomics Provides Update on RosettaGX Reveal(TM)Rosetta Genomics Provides Update on RosettaGX Reveal(TM)
finance.yahoo.com - November 20 at 9:25 AM
Rosetta Genomics Expands Patent Protection for Thyroid microRNA Biomarkers with U.S. Patent AllowanceRosetta Genomics Expands Patent Protection for Thyroid microRNA Biomarkers with U.S. Patent Allowance
finance.yahoo.com - November 14 at 7:27 AM
Critical Survey: Rosetta Genomics (ROSG) versus Its RivalsCritical Survey: Rosetta Genomics (ROSG) versus Its Rivals
www.americanbankingnews.com - November 11 at 3:28 PM
Rosetta Genomics Receives NASDAQ NotificationRosetta Genomics Receives NASDAQ Notification
finance.yahoo.com - November 9 at 12:39 PM
Rosetta Genomics Ltd (ROSG): Time For A Financial Health CheckRosetta Genomics Ltd (ROSG): Time For A Financial Health Check
finance.yahoo.com - November 4 at 12:16 PM
Rosetta Genomics (ROSG) Says Favorable Data from Independent Study Comparing RosettaGX Reveal versus Afirma Presented at American Thyroid AssociationRosetta Genomics (ROSG) Says Favorable Data from Independent Study Comparing RosettaGX Reveal versus Afirma Presented at American Thyroid Association
www.streetinsider.com - October 24 at 9:24 AM
Favorable Data from Independent Study Comparing RosettaGX Reveal(TM) versus Afirma(R) to Accurately Classify Indeterminate Thyroid Nodules Were Presented at the 87th Annual Meeting of the American Thyroid AssociationFavorable Data from Independent Study Comparing RosettaGX Reveal(TM) versus Afirma(R) to Accurately Classify Indeterminate Thyroid Nodules Were Presented at the 87th Annual Meeting of the American Thyroid Association
finance.yahoo.com - October 24 at 9:24 AM
Rosetta Genomics Ltd. (ROSG) Set to Announce Quarterly Earnings on WednesdayRosetta Genomics Ltd. (ROSG) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 6:46 AM
The Worldwide Market for Lab-Developed Test Services and the Market for Instruments and Reagents Sold to LabsThe Worldwide Market for Lab-Developed Test Services and the Market for Instruments and Reagents Sold to Labs
www.bizjournals.com - October 18 at 1:29 AM
Rosetta Genomics Expands Patent Estate for Thyroid Cancer Detection microRNA Biomarkers with U.S. Patent AllowanceRosetta Genomics Expands Patent Estate for Thyroid Cancer Detection microRNA Biomarkers with U.S. Patent Allowance
finance.yahoo.com - October 17 at 3:23 PM
RosettaGX Reveal to be Highlighted in Poster Presentations at the 87th Annual Meeting of the American Thyroid AssociationRosettaGX Reveal to be Highlighted in Poster Presentations at the 87th Annual Meeting of the American Thyroid Association
finance.yahoo.com - October 17 at 6:53 AM
Rosetta Genomics and MediNcrease Health Plans Announce Provider Agreement Expanding Access to RosettaGX(TM) Reveal and Other Testing ServicesRosetta Genomics and MediNcrease Health Plans Announce Provider Agreement Expanding Access to RosettaGX(TM) Reveal and Other Testing Services
finance.yahoo.com - October 13 at 8:51 AM
Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial ResultsRosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results
finance.yahoo.com - October 11 at 7:14 AM
How Does Rosetta Genomics Ltd (ROSG) Affect Your Portfolio Returns?How Does Rosetta Genomics Ltd (ROSG) Affect Your Portfolio Returns?
finance.yahoo.com - October 6 at 7:29 AM

SEC Filings

Rosetta Genomics (NASDAQ:ROSG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rosetta Genomics (NASDAQ:ROSG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rosetta Genomics (NASDAQ ROSG) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.